Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
6.3 ^USD	-4.55%		+0.64%	-29.92%

May. 07	Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	MT
May. 06	Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 05, 2022 at 05:00 pm EDT

Travere Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 48.49 million compared to USD 47.41 million a year ago. Net loss was USD 75.97 million compared to USD 53.87 million a year ago. Basic loss per share from continuing operations was USD 1.2 compared to USD 0.96 a year ago.

Latest news about Travere Therapeutics, Inc.

Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	May. 07	MT
Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Transcript : Travere Therapeutics, Inc., Q1 2024 Earnings Call, May 06, 2024	May. 06
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, vs. Street Est of $43.6M	May. 06	MT
EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	Apr. 24	MT
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	Apr. 24	MT
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	Apr. 24	CI
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	Apr. 03	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Transcript : Travere Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM	Mar. 12
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy	Mar. 11	MT
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy	Mar. 11	CI
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease	Feb. 23	MT
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy	Feb. 23	CI
Travere drug for rare kidney condition recommended for EU approval	Feb. 23	RE
Transcript : Travere Therapeutics, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q4 Revenue $45.1M, vs. Street Est of $41.8M	Feb. 15	MT
Travere Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Wedbush Lifts Travere Therapeutics' Price Target to $13 From $12, Keeps Outperform Rating	Jan. 29	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	Jan. 26	MT
Travere Therapeutics Signs Licensing Agreement With Renalys Pharma for Rare Kidney Disease Therapy	Jan. 26	MT
Travere Therapeutics, Inc. Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations	Jan. 25	CI
Transcript : Travere Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:45 PM	Jan. 09
Travere Therapeutics Expects $40 Million in Q4 Net Product Sales	Jan. 08	MT
Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	Jan. 08	CI

Chart Travere Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Companyâs Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - BofA Securities Health Care Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Travere Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.3 USD

Average target price

14.86 USD

Spread / Average Target

+135.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TRAVERE THERAPEUTICS, INC.	-29.92%	480M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs